Renalytix receives Nasdaq delisting notice; intends to appeal by June 28

Renalytix plc

Nasdaq determined company did not regain compliance with minimum bid price ($1.00) and MVLS ($50M) by June 19, 2024.
Unless appeal is filed by June 28, ADS trading will be suspended at opening on July 2, 2024, and Form 25-NSE filed.
Company intends to request a hearing before Nasdaq Hearings Panel, which will stay suspension pending decision.
Plan to present a strategic plan to regain compliance; no assurance of acceptance or success.
Delisting could impair liquidity, accurate quotations, and ability to raise capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.